Royalty Pharma and PureTech Health enter into KarXT royalty agreement

Client(s) Royalty Pharma

Jones Day advised Royalty Pharma in the acquisition of an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million, with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones.